Author/Editor		Schernthaner, Guntram; Karasik, Avraham; Abraitiené, Agné; Ametov, Alexander S.; Gaàl, Zsolt; Gumprecht, Janusz; Janež, Andrej; Kaser, Susanne; Lalić, Katarina; Mankovsky, Boris N.
Title		Evidence from routine clinical practice
Type		članek
Vol. and No.		Letnik 18, št. 1
Publication year		2019
Volume		str. 1-9
ISSN		1475-2840 - Cardiovascular diabetology
Language		eng
Abstract		EMPA-REG OUTCOME is recognised by international guidelines as a landmark study that showed a significant car-dioprotective benefit with empagliflozin in patients with type 2 diabetes (T2D) and cardiovascular disease. To assess the impact of empagliflozin in routine clinical practice, the ongoing EMPRISE study is collecting real-world evidence to compare effectiveness, safety and health economic outcomes between empagliflozin and DPP-4 inhibitors. A planned interim analysis of EMPRISE was recently published, confirming a substantial reduction in hospitalisation for heart failure with empagliflozin across a diverse patient population. In this commentary article, we discuss the new data in the context of current evidence and clinical guidelines, as clinicians experienced in managing cardiovascular risk in patients with T2D. We also look forward to what future insights EMPRISE may offer, as evidence is accumulated over the next years to complement the important findings of EMPA-REG OUTCOME.
Keywords		type 2 diabetes CVOTs real-world evidence EMPRISE EMPA-REG OUTCOME heart failure